132 related articles for article (PubMed ID: 18478936)
21. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Wang MZ; Zhong W; Zhang L; Li LY; Wang SL; Li JR; Zhang XT
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):221-4. PubMed ID: 18756941
[TBL] [Abstract][Full Text] [Related]
23. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
26. [Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Zhou SW; Ren SX; Yan LH; Zhang L; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):469-72. PubMed ID: 19024526
[TBL] [Abstract][Full Text] [Related]
27. [Gefitinib target treatment in non-small cell lung cancer].
Wu YL; Yang JJ; Lin JY; Huang YJ; Liao RQ; Huang YS; Zhou Q; Xu CR; Wang Z
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):98-102. PubMed ID: 17445469
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
[TBL] [Abstract][Full Text] [Related]
29. [Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Zhao YY; Zhang Y; Zhao HY; Wu JX; Jiang W; Xue C; Zhang L
Ai Zheng; 2009 Jun; 28(6):626-31. PubMed ID: 19635201
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
31. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
32. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Takahashi K; Saito H; Hasegawa Y; Ando M; Yamamoto M; Kojima E; Sugino Y; Kimura T; Nomura F; Ogasawara T; Shindoh J; Yoshida N; Suzuki R
Cancer Chemother Pharmacol; 2014 Oct; 74(4):721-7. PubMed ID: 25087097
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of non-small cell lung cancer with gefitinib].
Zhang XT; Li LY; Wang SL; Mu XL; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):180-3. PubMed ID: 15854414
[TBL] [Abstract][Full Text] [Related]
34. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
Yin YM; Geng YT; Shao YF; Hu XL; Li W; Shu YQ; Wang ZX
J Exp Clin Cancer Res; 2010 Sep; 29(1):126. PubMed ID: 20843324
[TBL] [Abstract][Full Text] [Related]
35. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Sunaga N; Tomizawa Y; Yanagitani N; Iijima H; Kaira K; Shimizu K; Tanaka S; Suga T; Hisada T; Ishizuka T; Saito R; Dobashi K; Mori M
Lung Cancer; 2007 Jun; 56(3):383-9. PubMed ID: 17368623
[TBL] [Abstract][Full Text] [Related]
36. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
37. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
[TBL] [Abstract][Full Text] [Related]
38. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
39. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Veronese ML; Algazy K; Bearn L; Eaby B; Alavi J; Evans T; Stevenson JP; Shults J
Cancer Invest; 2005; 23(4):296-302. PubMed ID: 16100941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]